Latest Deals
The deal marks the second time Novartis has tapped Monte Rosa’s services in just under year. Credit: Taljat David/Shutterstock.com
Novartis returns to Monte Rosa for second time in a year with $5.7bn deal
Novartis has ventured back to Monte Rosa Therapeutics tasked with finding more immune-mediated disease drug candidates, signing a licensing deal worth up to $5.7bn. The agreement will see Novartis pay $120m upfront to Monte Rosa. Optional and milestone payments, as well as royalties on any drugs commercialised from the partnership, could see the total deal value reach $5.7bn.
GSK plans $30bn investment for R&D in US
GSK has announced an investment of $30bn in the US over the next five years for research and development (R&D) and supply chain infrastructure. The investment includes a $1.2bn package for advanced manufacturing, AI and digital technologies. GSK said the package will support new biopharma factories and laboratories.
Roche signs agreement to acquire 89bio in $2.4bn deal
Roche has signed a definitive merger agreement for the acquisition of clinical-stage biopharmaceutical company 89bio, for a total equity value of around $2.4bn. Under the deal, Roche will initiate a tender offer to purchase all outstanding shares of 89bio common stock at $14.50 per share in cash. This will also include a non-tradeable contingent value right (CVR) that could yield payments of up to $6 per share based on specific milestones.
Kriya gains $320m in Series D for gene therapy development
Kriya Therapeutics has closed an oversubscribed Series D funding round, raising $320m, aimed at propelling its gene therapy pipeline targeting chronic diseases with significant unmet medical needs. The investment round was jointly led by Premji Invest and Patient Square Capital, with contributions from a consortium of life sciences and technology investors, including Narya Capital, Peter Thiel, The T1D Fund: A Breakthrough T1D Venture and several long-standing backers.
